BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Islet Sciences Appoints Dr. Kevan Herold and Dr. Morton Printz to Scientific Advisory Board


9/6/2012 11:18:34 AM

NEW YORK, Sept. 6, 2012 /PRNewswire/ -- Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced the following additions to its Scientific Advisory Board: Dr. Kevan Herold and Dr. Morton Printz.

"These key additions to our Scientific Advisory Board are demonstrative of our progress, and the leading edge therapies for diabetes that we are focused on providing," stated Dr. Jonathan Lakey, Chief Scientific Officer and Chairman of the Scientific Advisory Board of Islet Sciences. "As we bolster our overall team we are proud to add these esteemed scientists and research physicians to our organization."

"I am pleased to announce these additions to our Scientific Advisory Board as we continue to make significant progress on our growth strategy," said John Steel, Chairman and CEO of Islet Sciences. "The expertise and deep industry relationships this esteemed group brings along with their significant knowledge in the field of diabetes will be quite helpful as the company moves forward."

Dr. Kevan Herold
Dr. Herold is a Professor of Immunobiology and Medicine at Yale University. His work in the field of Type 1 diabetes is well known, including his pioneering work with Dr. Jeff Bluestone that showed the efficacy of anti-CD3 mAb treatment of Type 1 diabetes. His work is translational, bridging the fields of basic immunology, clinical trials, and clinical medicine, which will enable this Program to rapidly move advances in preclinical studies to clinical testing. Much of his recent work pertains to the mechanisms of immune regulation by anti-CD3 mAb in patients, which forms the basis for studies in this Program. He has long standing collaborations with Dr. Bluestone and with Dr. Mattias von Herrath. Finally, Dr. Herold is the Principal Investigator on 3 clinical trials supported by the Immune Tolerance Network, and TrialNet. Dr. Herold is an Endocrinologist with a special interest in autoimmune diseases and diabetes and sees both adolescent and adult patients with all forms of diabetes and other metabolic disorders. Dr. Herold is conducting research on immunotherapy for treatment of Type 1 diabetes. Dr. Herold's laboratory work involves studies of induction of immunologic tolerance to autoimmunity.

Dr. Morton Printz
Dr. Morton Printz is Professor Emeritus in Pharmacology at the University of California San Diego. Dr. Printz trained at the University of Pittsburgh receiving a B.Sc. degree (Pharmacy) and a Ph.D. in Biophysics. Following postdoctoral training at Dartmouth and an appointment at Rockefeller University, he joined the UC San Diego School of Medicine in 1972. His research at Dartmouth and Rockefeller focused on conformational dynamics of nucleic acids, peptides and proteins using the newly developed method of tritium-hydrogen exchange (THX). Conformational studies on angiotensin and angiotensinogen led to research on hypertension, specifically origins of essential hypertension and metabolic syndrome. In addition to NIH RO1 and other grants, he was Director of an NIH-NHLBI funded Specialized Center or Research Program in hypertension (SCOR-Hypertension) and subsequently Director of four NIH Program Project Grants on hypertension mechanisms. He has been involved as collaborator, researcher and advisor in investigations on eicosanoid mechanisms in hypertension, ductus arteriosus, blood vessels, cardiac remodeling and asthma, and biotech-funded special projects related to drug development for metabolic syndrome and hypertension. Using a rat recombinant inbred strain colony he has conducted original, collaborative and advisory studies with these strains on hypertension genetics, stress-cardiovascular response, metabolic syndrome, insulin resistance, behavior, gonadal radiation sensitivity and anthrax toxin. His recent research has focused on brown adipose tissue and the origins of hypertension, insulin resistance and metabolic syndrome.

About Islet Sciences, Inc.
Islet Sciences is a development-stage biotechnology company with patented technologies focused on transplantation therapy for people with insulin-dependent diabetes. The Company's transplantation technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. The Company's mission includes the introduction of commercial products with applications to cell-based replacement therapy in the healthcare marketplace.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements for Islet Sciences reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the companies' successful execution of their perspective business strategies, including with respect to the successful development of cell therapeutics, including with respect to Islet Sciences as well as the future of the cell therapeutics industry. Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements on September 30, 2011 and for Islet include the risks described in the One E-Commerce Corporation Form 8-K filed with the Securities and Exchange Commission on December 30, 2011. The companies' further development is highly dependent on future medical and research developments and market acceptance, which is outside their control.

Investor Contact:
Jeff Ramson
ProActive Capital Group
(646) 863-6893
ramson@proactivecrg.com

SOURCE Islet Sciences, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->